Lortab and Scarlet fever - a phase IV clinical study of FDA data

Summary:

Scarlet fever is reported as a side effect among people who take Lortab (acetaminophen; hydrocodone bitartrate), especially for people who are female, 60+ old, also take Lexapro, and have Metastatic neoplasm.

The phase IV clinical study analyzes which people have Scarlet fever when taking Lortab. It is created by eHealthMe based on reports of 29,547 people who have side effects when taking Lortab from the FDA, and is updated regularly.

What is Lortab?

Lortab has active ingredients of acetaminophen; hydrocodone bitartrate. It is often used in pain. eHealthMe is studying from 31,285 Lortab users. Check the latest studies of Lortab.

What is Scarlet fever?

Scarlet fever (a disease caused by a toxin (erythrogenic exotoxin) released by streptococcus pyogenes) is found to be associated with 93 drugs and 171 conditions by eHealthMe. Check the latest studies of Scarlet fever.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

29,547 people reported to have side effects when taking Lortab.
Among them, 20 people (0.07%) have Scarlet fever.

Among these 20 people:

What is the gender of people who have Scarlet fever when taking Lortab? *

female: 95 %
male: 5 %

What is the age of people who have Scarlet fever when taking Lortab? *

What are other drugs people take besides Lortab? *

What are other side effects people have besides Scarlet fever? *

Mumps (a virus that can lead to swelling and pain in the salivary glands, along with fever, loss of appetite, and fatigue): 20 people, 100.00%
Kidney Infection: 20 people, 100.00%
Oedema (fluid collection in tissue): 20 people, 100.00%
Osteonecrosis Of Jaw (death of bone of jaw): 20 people, 100.00%
Osteopenia (a condition where bone mineral density is lower than normal): 20 people, 100.00%
Osteoporosis (bones weak and more likely to break): 20 people, 100.00%
Bone Lesion (bone with abnormalities. bone lesions can result from growth formations, infections, or injuries): 20 people, 100.00%
Constipation: 20 people, 100.00%
Bronchitis (inflammation of the mucous membrane in the bronchial tubes): 20 people, 100.00%
Pneumonia: 20 people, 100.00%

What are the existing conditions these people have? *

Metastatic Neoplasm (spreadable cancer tumour): 20 people, 100.00%
Breast Cancer Metastatic: 18 people, 90.00%
Hypersensitivity: 12 people, 60.00%
Diabetes: 12 people, 60.00%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 1 person, 5.00%
Metastases To Bone (cancer spreads to bone): 1 person, 5.00%

* Approximation only. Some reports may have incomplete information.

Do you take Lortab and have Scarlet fever?

- Check whether Scarlet fever is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Lortab:

Lortab (31,285 reports)

Scarlet fever treatments and more:

Scarlet fever (520 reports)

How severe was Scarlet fever and when was it recovered:

Scarlet fever in Lortab

Expand to all the drugs that have ingredients of acetaminophen; hydrocodone bitartrate:

Scarlet fever and drugs with ingredients of acetaminophen; hydrocodone bitartrate (26 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Lortab:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Scarlet fever:

Scarlet fever (93 drugs)

Browse all the conditions that are associated with Scarlet fever:

Scarlet fever (171 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on acetaminophen; hydrocodone bitartrate (the active ingredients of Lortab) and Lortab (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.